½ÃÀ庸°í¼­
»óǰÄÚµå
1512791

¾à¹°°¨½Ã ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® ¸®Æ÷Æ® : ¼­ºñ½ºº°, Á¦Ç°¼ö¸íÁֱ⺰, À¯Çüº°, ÇÁ·Î¼¼½º Ç÷ο캰, Ä¡·á ¿µ¿ªº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ºÎ¹®º° ¿¹Ãø(2024-2032³â)

Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 117 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 137¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ Á¶»ç ¸®Æ÷Æ®´Â ÇöÀç ½ÃÀå ¿ªÇÐÀÇ »ó¼¼ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ °üÇÑ ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ¾à¹° ¼·Ãë·® Áõ°¡, ½Å¾à °³¹ß ºóµµ Áõ°¡, ¾à¹° ¹ÝÀÀ À½¼º ¹× ¾à¹° µ¶¼º °¡°Ý »ó½Â, ¾à¹°°¨½Ã ¼Ö·ç¼ÇÀÇ °è¾à Ãß¼¼ È®´ë µîÀÌ ¾÷°è ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ Á¦¾à ºÎ¹®ÀÇ °úµµÇÑ ÁöÃâ, ¾à¹° ºÎÀÛ¿ë ¹ß»ý·ü Áõ°¡, ¾à¹° ¿À·ù·Î ÀÎÇØ ¾÷°è°¡ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Äڷγª¹ÙÀÌ·¯½º Àü¿°º´Àº ¹é½Å¿¡ ´ëÇÑ ±ä±ÞÇÑ ¼ö¿ä¸¦ âÃâÇÏ¿© ¾÷°è Âü°¡Àڵ鿡°Ô ¸î °¡Áö ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

°íÁ¤ÀûÀÎ °ø±Þ ºñ¿ëÀ» º¯µ¿ ºñ¿ëÀ¸·Î ÀüȯÇϰí, ÁÖ¹®Çü Àü¹® Áö½Ä¿¡ ´ëÇÑ ¿Âµð¸Çµå Á¢±Ù¼º µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ¾Æ¿ô¼Ò½Ì °è¾à ºÎ¹®ÀÌ ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ½Å¾à µµÀÔ¿¡ ´ëÇÑ ¾÷°è ±â¾÷ÀÇ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¹Ì±¹°ú ij³ª´Ù¿Í °°Àº ±¹°¡¿¡¼­´Â ÷´ÜÈ­µÈ ÀÇ·á ½Ã½ºÅÛÀÇ Á¸Àç¿Í ÇÔ²² ¾ö°ÝÇÑ ±ÔÁ¦°¡ ¾÷°è ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå ÀλçÀÌÆ®

  • ¾à¹°°¨½Ã - ¾÷°è ½º³À¼ô
  • ¾à¹°°¨½Ã ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
      • ¸¸¼ºÁúȯÀÇ ¸¸¿¬
      • ÀǾàǰ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
    • ¾ïÁ¦¿äÀΰú °úÁ¦
      • µ¥ÀÌÅÍ °ü¸®¿¡ °üÇÑ ¹®Á¦
  • PESTLE ºÐ¼®
  • ¾à¹°°¨½Ã ¾÷°èÀÇ µ¿Çâ
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • »ç³»
  • °è¾à ¾Æ¿ô¼Ò½Ì

Á¦6Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : Á¦Ç°¼ö¸íÁֱ⺰

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÀüÀÓ»ó
  • ´Ü°è I
  • ´Ü°è II
  • ´Ü°è III
  • ´Ü°è IV

Á¦7Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : Ä¡·á ¿µ¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Á¾¾çÇÐ
  • ½Å°æÇÐ
  • ½ÉÀ庴ÇÐ
  • È£Èí±â
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : ÇÁ·Î¼¼½º Ç÷ο캰

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÄÉÀ̽º µ¥ÀÌÅÍ °ü¸®
  • ½ÅÈ£ ŽÁö
  • ¸®½ºÅ© °ü¸® ½Ã½ºÅÛ

Á¦9Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÀÚ¹ßÀû º¸°í
  • ADR º¸°í °­È­
  • Ç¥Àû ÀÚ¹ßÀû º¸°í
  • ÄÚȣƮ À̺¥Æ® ¸ð´ÏÅ͸µ
  • EHR ¸¶ÀÌ´×

Á¦10Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • ÀǾàǰ
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ÀÇ·á±â±â Á¦Á¶¾÷ü
  • ±âŸ

Á¦11Àå ¼¼°èÀÇ ¾à¹°°¨½Ã ½ÃÀå : Áö¿ª

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¾à¹°°¨½Ã ½ÃÀåÀÇ Æò°¡ : Áö¿ªº°, 2019-2032³â
  • ºÏ¹Ì
    • ºÏ¹Ì : ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, 2019-2032³â
    • ºÏ¹Ì : ÇÁ·Î¼¼½º Ç÷ο캰, 2019-2032³â
    • ºÏ¹Ì : Á¦Ç°¼ö¸íÁֱ⺰, 2019-2032³â
    • ºÏ¹Ì : À¯Çüº°, 2019-2032³â
    • ºÏ¹Ì : Ä¡·á ¿µ¿ªº°, 2019-2032³â
    • ºÏ¹Ì : ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, 2019-2032³â
    • À¯·´ : ÇÁ·Î¼¼½º Ç÷ο캰, 2019-2032³â
    • À¯·´ : Á¦Ç°¼ö¸íÁֱ⺰, 2019-2032
    • À¯·´ : À¯Çüº°, 2019-2032
    • À¯·´ : Ä¡·á ¿µ¿ªº°, 2019-2032³â
    • À¯·´ : ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÇÁ·Î¼¼½º Ç÷ο캰, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç°¼ö¸íÁֱ⺰, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : À¯Çüº°, 2019-2032
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Ä¡·á ¿µ¿ªº°, 2019-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÇÁ·Î¼¼½º Ç÷ο캰, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç°¼ö¸íÁֱ⺰, 2019-2032
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : À¯Çüº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Ä¡·á ¿µ¿ªº°, 2019-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÇÁ·Î¼¼½º Ç÷ο캰, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç°¼ö¸íÁֱ⺰, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : À¯Çüº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : Ä¡·á ¿µ¿ªº°, 2019-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2019-2032³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª

Á¦12Àå °æÀï ±¸µµ

  • È®´ë¿Í Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦13Àå ±â¾÷ °³¿ä

  • Accenture
  • ArisGlobal
  • BioClinica, Inc
  • Capgemini
  • Clinquest Group B.V.(Linical Americas)
  • Cognizant
  • FMD K&L
  • IBM Corporation
  • ICON Plc.
  • IQVIA
  • ITClinical
  • Laboratory Corporation of America Holdings
  • Linical Accelovance
  • PAREXEL International Corporation
  • TAKE Solutions
  • United BioSource Corporation
  • Wipro Limited
KSA 24.07.19

The global pharmacovigilance market size is expected to reach USD 13.75 Billion by 2032 according to a new study by Polaris Market Research. The report "Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers of the market include rising medication intake novel drug development frequencies, rising prices of negative drug responses and drug toxicities, as well as an expanding tendency of contracting pharmacovigilance solutions is expected to boost the industry growth. Moreover, the pharmaceutical sector's excessive expenditure, rising incidence of adverse drug events, and drug mistakes are propelling the industry forward. Furthermore, the coronavirus pandemic has produced an emergency demand for a vaccine that has offered several chances for industry participants.

The contract outsources segment is expected to hold the major shares in the global market during the forecast period due to its benefits such as transforming fixed supply costs into variables, refining on-demand contact to distinctive expertise along with other benefits.

North America is expected to hold the major share in the global market over the forecast period due to increasing investment by the industry players in introducing novel drugs. Moreover, stringent regulations along with the presence of advanced healthcare systems in countries like the U.S. and Canada are expected to create lucrative opportunities for industry growth.

Some of the major players operating in the global market are ArisGlobal, Accenture, BioClinica, Inc., United BioSource Corporation, Clinquest Group B.V. (Linical Americas), Cognizant, Capgemini, FMD K&L, IBM Corporation, IQVIA, ICON Plc., ITClinical, Linical Accelovance, PAREXEL International Corporation, Laboratory Corporation of America Holdings, TAKE Solutions, and Wipro Limited.

Polaris Market Research has segmented the pharmacovigilance market report on the basis of service provider, product life cycle, type, process flow, therapeutic area, end-use, and region:

Pharmacovigilance, Service Provider Outlook (Revenue - USD Billion, 2019-2032)

  • In-house
  • Contract Outsourcing

Pharmacovigilance, Product Life Cycle Outlook (Revenue - USD Billion, 2019-2032)

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Pharmacovigilance, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance, Process Flow Outlook (Revenue - USD Billion, 2019-2032)

  • Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing & Reporting
  • Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review & Reporting
  • Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Pharmacovigilance, Therapeutic Area Outlook (Revenue - USD Billion, 2019-2032)

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

Pharmacovigilance, End-Use Outlook (Revenue - USD Billion, 2019-2032)

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Pharmacovigilance, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • Italy
  • France
  • Netherlands
  • Russia
  • Spain
  • Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacovigilance Market Insights

  • 4.1. Pharmacovigilance - Industry Snapshot
  • 4.2. Pharmacovigilance Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of chronic disease
      • 4.2.1.2. Increasing investment in drug development
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Issues related to data management
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacovigilance Industry Trends
  • 4.6. COVID-19 Impact Analysis

5. Global Pharmacovigilance Market, by Service Provider

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 5.3. In-house
    • 5.3.1. Global Pharmacovigilance Market, by In-house, by Region, 2019-2032 (USD Billion)
  • 5.4. Contract Outsourcing
    • 5.4.1. Global Pharmacovigilance Market, by Contract Outsourcing, by Region, 2019-2032 (USD Billion)

6. Global Pharmacovigilance Market, by Product Life Cycle

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 6.3. Pre-clinical
    • 6.3.1. Global Pharmacovigilance Market, by Pre-clinical, by Region, 2019-2032 (USD Billion)
  • 6.4. Phase I
    • 6.4.1. Global Pharmacovigilance Market, by Phase I, by Region, 2019-2032 (USD Billion)
  • 6.5. Phase II
    • 6.5.1. Global Pharmacovigilance Market, by Phase II, by Region, 2019-2032 (USD Billion)
  • 6.6. Phase III
    • 6.6.1. Global Pharmacovigilance Market, by Phase III, by Region, 2019-2032 (USD Billion)
  • 6.7. Phase IV
    • 6.7.1. Global Pharmacovigilance Market, by Phase IV, by Region, 2019-2032 (USD Billion)

7. Global Pharmacovigilance Market, by Therapeutic Area

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 7.3. Oncology
    • 7.3.1. Global Pharmacovigilance Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 7.4. Neurology
    • 7.4.1. Global Pharmacovigilance Market, by Neurology, by Region, 2019-2032 (USD Billion)
  • 7.5. Cardiology
    • 7.5.1. Global Pharmacovigilance Market, by Cardiology, by Region, 2019-2032 (USD Billion)
  • 7.6. Respiratory Systems
    • 7.6.1. Global Pharmacovigilance Market, by Respiratory Systems, by Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Other Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

8. Global Pharmacovigilance Market, by Process Flow

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 8.3. Case Data Management
    • 8.3.1. Global Pharmacovigilance Market, by Case Data Management, by Region, 2019-2032 (USD Billion)
    • 8.3.2. Case Logging
      • 8.3.2.1. Global Pharmacovigilance Market, by Case Logging, by Region, 2019-2032 (USD Billion)
    • 8.3.3. Case Data Analysis
      • 8.3.3.1. Global Pharmacovigilance Market, by Case Data Analysis, by Region, 2019-2032 (USD Billion)
    • 8.3.4. Medical Reviewing & Reporting
      • 8.3.4.1. Global Pharmacovigilance Market, by Medical Reviewing & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.4. Signal Detection
    • 8.4.1. Global Pharmacovigilance Market, by Signal Detection, by Region, 2019-2032 (USD Billion)
    • 8.4.2. Adverse Event Logging
      • 8.4.2.1. Global Pharmacovigilance Market, by Adverse Event Logging, by Region, 2019-2032 (USD Billion)
    • 8.4.3. Adverse Event Analysis
      • 8.4.3.1. Global Pharmacovigilance Market, by Adverse Event Analysis, by Region, 2019-2032 (USD Billion)
    • 8.4.4. Adverse Event Review & Reporting
      • 8.4.4.1. Global Pharmacovigilance Market, by Adverse Event Review & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.5. Risk Management System
    • 8.5.1. Global Pharmacovigilance Market, by Risk Management System, by Region, 2019-2032 (USD Billion)
    • 8.5.2. Risk Evaluation System
      • 8.5.2.1. Global Pharmacovigilance Market, by Risk Evaluation System, by Region, 2019-2032 (USD Billion)
    • 8.5.3. Risk Mitigation System
      • 8.5.3.1. Global Pharmacovigilance Market, by Risk Mitigation System, by Region, 2019-2032 (USD Billion)

9. Global Pharmacovigilance Market, by Type

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 9.3. Spontaneous Reporting
    • 9.3.1. Global Pharmacovigilance Market, by Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.4. Intensified ADR Reporting
    • 9.4.1. Global Pharmacovigilance Market, by Intensified ADR Reporting, by Region, 2019-2032 (USD Billion)
  • 9.5. Targeted Spontaneous Reporting
    • 9.5.1. Global Pharmacovigilance Market, by Targeted Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.6. Cohort Event Monitoring
    • 9.6.1. Global Pharmacovigilance Market, by Cohort Event Monitoring, by Region, 2019-2032 (USD Billion)
  • 9.7. EHR Mining
    • 9.7.1. Global Pharmacovigilance Market, by EHR Mining, by Region, 2019-2032 (USD Billion)

10. Global Pharmacovigilance Market, by End-Use

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Global Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 10.3. Pharmaceuticals
    • 10.3.1. Global Pharmacovigilance Market, by Pharmaceuticals, by Region, 2019-2032 (USD Billion)
  • 10.4. Biotechnology Companies
    • 10.4.1. Global Pharmacovigilance Market, by Biotechnology Companies, by Region, 2019-2032 (USD Billion)
  • 10.5. Medical Device Manufacturers
    • 10.5.1. Global Pharmacovigilance Market, by Medical Device Manufacturers, by Region, 2019-2032 (USD Billion)
  • 10.6. Others
    • 10.6.1. Global Other End-Uses Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

11. Global Pharmacovigilance Market, by Geography

  • 11.1. Key findings
  • 11.2. Introduction
    • 11.2.1. Pharmacovigilance Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 11.3. Pharmacovigilance Market - North America
    • 11.3.1. North America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.3.2. North America: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.3.3. North America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.3.4. North America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.3.5. North America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.3.6. North America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.7. Pharmacovigilance Market - U.S.
      • 11.3.7.1. U.S.: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.7.2. U.S.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.7.3. U.S.: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.7.4. U.S.: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.7.5. U.S.: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.7.6. U.S.: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.8. Pharmacovigilance Market - Canada
      • 11.3.8.1. Canada: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.8.2. Canada.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.8.3. Canada: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.8.4. Canada: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.8.5. Canada: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.8.6. Canada: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4. Pharmacovigilance Market - Europe
    • 11.4.1. Europe: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.2. Europe.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.3. Europe: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.4. Europe: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.5. Europe: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.6. Europe: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.7. Pharmacovigilance Market - UK
      • 11.4.7.1. UK: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.7.2. UK.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.7.3. UK: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.7.4. UK: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.7.5. UK: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.7.6. UK: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.8. Pharmacovigilance Market - France
      • 11.4.8.1. France: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.8.2. France.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.8.3. France: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.8.4. France: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.8.5. France: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.8.6. France: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.9. Pharmacovigilance Market - Germany
      • 11.4.9.1. Germany: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.9.2. Germany.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.9.3. Germany: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.9.4. Germany: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.9.5. Germany: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.9.6. Germany: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.10. Pharmacovigilance Market - Italy
      • 11.4.10.1. Italy: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.10.2. Italy.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.10.3. Italy: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.10.4. Italy: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.10.5. Italy: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.10.6. Italy: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.11. Pharmacovigilance Market - Spain
      • 11.4.11.1. Spain: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.11.2. Spain.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.11.3. Spain: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.11.4. Spain: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.11.5. Spain: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.11.6. Spain: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.12. Pharmacovigilance Market - Netherlands
      • 11.4.12.1. Netherlands: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.12.2. Netherlands.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.12.3. Netherlands: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.12.4. Netherlands: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.12.5. Netherlands: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.12.6. Netherlands: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.13. Pharmacovigilance Market - Russia
      • 11.4.13.1. Russia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.13.2. Russia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.13.3. Russia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.13.4. Russia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.13.5. Russia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.13.6. Russia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5. Pharmacovigilance Market - Asia Pacific
    • 11.5.1. Asia Pacific: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.2. Asia Pacific.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.3. Asia Pacific: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.4. Asia Pacific: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.5. Asia Pacific: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.6. Asia Pacific: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.7. Pharmacovigilance Market - China
      • 11.5.7.1. China: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.7.2. China.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.7.3. China: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.7.4. China: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.7.5. China: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.7.6. China: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.8. Pharmacovigilance Market - India
      • 11.5.8.1. India: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.8.2. India.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.8.3. India: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.8.4. India: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.8.5. India: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.8.6. India: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.9. Pharmacovigilance Market - Japan
      • 11.5.9.1. Japan: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.9.2. Japan.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.9.3. Japan: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.9.4. Japan: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.9.5. Japan: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.9.6. Japan: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.10. Pharmacovigilance Market - Malaysia
      • 11.5.10.1. Malaysia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.10.2. Malaysia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.10.3. Malaysia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.10.4. Malaysia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.10.5. Malaysia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.10.6. Malaysia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.11. Pharmacovigilance Market - Indonesia
      • 11.5.11.1. Indonesia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.11.2. Indonesia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.11.3. Indonesia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.11.4. Indonesia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.11.5. Indonesia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.11.6. Indonesia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.12. Pharmacovigilance Market - South Korea
      • 11.5.12.1. South Korea: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.12.2. South Korea.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.12.3. South Korea: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.12.4. South Korea: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.12.5. South Korea: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.12.6. South Korea: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6. Pharmacovigilance Market - Middle East & Africa
    • 11.6.1. Middle East & Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.2. Middle East & Africa: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.3. Middle East & Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.4. Middle East & Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.5. Middle East & Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.6. Middle East & Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.7. Pharmacovigilance Market - Saudi Arabia
      • 11.6.7.1. Saudi Arabia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.7.2. Saudi Arabia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.7.3. Saudi Arabia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.7.4. Saudi Arabia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.7.5. Saudi Arabia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.7.6. Saudi Arabia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.8. Pharmacovigilance Market - UAE
      • 11.6.8.1. UAE: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.8.2. UAE.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.8.3. UAE: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.8.4. UAE: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.8.5. UAE: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.8.6. UAE: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.9. Pharmacovigilance Market - Israel
      • 11.6.9.1. Israel: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.9.2. Israel.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.9.3. Israel: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.9.4. Israel: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.9.5. Israel: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.9.6. Israel: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.10. Pharmacovigilance Market - South Africa
      • 11.6.10.1. South Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.10.2. South Africa.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.10.3. South Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.10.4. South Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.10.5. South Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.10.6. South Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7. Pharmacovigilance Market - Latin America
    • 11.7.1. Latin America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.2. Latin America.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.3. Latin America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.4. Latin America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.5. Latin America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.6. Latin America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.7. Pharmacovigilance Market - Mexico
      • 11.7.7.1. Mexico: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.7.2. Mexico.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.7.3. Mexico: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.7.4. Mexico: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.7.5. Mexico: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.7.6. Mexico: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.8. Pharmacovigilance Market - Brazil
      • 11.7.8.1. Brazil: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.8.2. Brazil.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.8.3. Brazil: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.8.4. Brazil: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.8.5. Brazil: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.8.6. Brazil: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.9. Pharmacovigilance Market - Argentina
      • 11.7.9.1. Argentina: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.9.2. Argentina.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.9.3. Argentina: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.9.4. Argentina: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.9.5. Argentina: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.9.6. Argentina: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)

12. Competitive Landscape

  • 12.1. Expansion and Acquisition Analysis
    • 12.1.1. Expansion
    • 12.1.2. Acquisitions
  • 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

  • 13.1. Accenture
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Benchmarking
    • 13.1.4. Recent Development
  • 13.2. ArisGlobal
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Benchmarking
    • 13.2.4. Recent Development
  • 13.3. BioClinica, Inc
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Benchmarking
    • 13.3.4. Recent Development
  • 13.4. Capgemini
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Benchmarking
    • 13.4.4. Recent Development
  • 13.5. Clinquest Group B.V. (Linical Americas)
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Benchmarking
    • 13.5.4. Recent Development
  • 13.6. Cognizant
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Benchmarking
    • 13.6.4. Recent Development
  • 13.7. FMD K&L
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Benchmarking
    • 13.7.4. Recent Development
  • 13.8. IBM Corporation
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Benchmarking
    • 13.8.4. Recent Development
  • 13.9. ICON Plc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Benchmarking
    • 13.9.4. Recent Development
  • 13.10. IQVIA
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Benchmarking
    • 13.10.4. Recent Development
  • 13.11. ITClinical
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Benchmarking
    • 13.11.4. Recent Development
  • 13.12. Laboratory Corporation of America Holdings
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Benchmarking
    • 13.12.4. Recent Development
  • 13.13. Linical Accelovance
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Benchmarking
    • 13.13.4. Recent Development
  • 13.14. PAREXEL International Corporation
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Benchmarking
    • 13.14.4. Recent Development
  • 13.15. TAKE Solutions
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Benchmarking
    • 13.15.4. Recent Development
  • 13.16. United BioSource Corporation
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Benchmarking
    • 13.16.4. Recent Development
  • 13.17. Wipro Limited
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Benchmarking
    • 13.17.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦